| 000 | 01501 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250517212132.0 | ||
| 264 | 0 | _c20181023 | |
| 008 | 201810s 0 0 eng d | ||
| 022 | _a1432-1041 | ||
| 024 | 7 |
_a10.1007/s00228-018-2461-1 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aUusalo, P | |
| 245 | 0 | 0 |
_aSubcutaneously administered dexmedetomidine is efficiently absorbed and is associated with attenuated cardiovascular effects in healthy volunteers. _h[electronic resource] |
| 260 |
_bEuropean journal of clinical pharmacology _cAug 2018 |
||
| 300 |
_a1047-1054 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdministration, Intravenous |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 |
_aCatecholamines _xblood |
| 650 | 0 | 4 | _aCross-Over Studies |
| 650 | 0 | 4 |
_aDexmedetomidine _xadministration & dosage |
| 650 | 0 | 4 | _aHealthy Volunteers |
| 650 | 0 | 4 |
_aHemodynamics _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypnotics and Sedatives _xpharmacology |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aSubcutaneous Absorption _xdrug effects |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aAl-Ramahi, D | |
| 700 | 1 | _aTilli, I | |
| 700 | 1 | _aAantaa, R A | |
| 700 | 1 | _aScheinin, M | |
| 700 | 1 | _aSaari, T I | |
| 773 | 0 |
_tEuropean journal of clinical pharmacology _gvol. 74 _gno. 8 _gp. 1047-1054 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00228-018-2461-1 _zAvailable from publisher's website |
| 999 |
_c28298701 _d28298701 |
||